Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
Harding JJ, Piha-Paul SA, Shah RH, Murphy JJ, Cleary JM, Shapiro GI, Quinn DI, Braña I, Moreno V, Borad M, Loi S, Spanggaard I, Park H, Ford JM, Arnedos M, Stemmer SM, de la Fouchardiere C, Fountzilas C, Zhang J, DiPrimeo D, Savin C, Duygu Selcuklu S, Berger MF, Eli LD, Meric-Bernstam F, Jhaveri K, Solit DB, Abou-Alfa GK.
Harding JJ, et al. Among authors: de la fouchardiere c.
Nat Commun. 2023 Feb 6;14(1):630. doi: 10.1038/s41467-023-36399-y.
Nat Commun. 2023.
PMID: 36746967
Free PMC article.